Key facts
- This page summarizes Margaret M. FitzPatrick's Form 4 filing for AN2 Therapeutics, Inc. (ANTX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 02 Sep 2026, 18:43.
Margaret M. FitzPatrick - 01 Sep 2026 Form 4 Insider Report for AN2 Therapeutics, Inc. (ANTX)
- Reporting relationship
- Director
- Issuer ticker
- ANTX
- Reported as of
- 01 Sep 2026
- Net transaction value
- +$11,602
- SEC form
- 4
- Accepted by SEC
- 02 Sep 2026, 18:43:59 UTC
- Prior SEC filing
- 23 Mar 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Lucy Day, Attorney-in-Fact for Margaret M. FitzPatrick
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Margaret M. FitzPatrick filed Form 4 for AN2 Therapeutics, Inc. (ANTX) on 02 Sep 2026.
Change
- Previous filing in this sequence was filed on 23 Mar 2026.
- Current net transaction value: +$11,602.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001873879
Primary reporting owner
FitzPatrick Margaret M
- Relationship
- Director
- Address
- C/O AN2 THERAPEUTICS, INC., 1300 EL CAMINO REAL, SUITE 100, MENLO PARK
- Signature
- /s/ Lucy Day, Attorney-in-Fact for Margaret M. FitzPatrick
- Signature date
- 02 Sep 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ANTX
transaction
Common Stock
Purchase
- Transaction value
- $11,602
- Shares
- +2,098
- Change %
- +24%
- Price
- $5.53
- Shares after
- 10,708
- Date
- 01 Sep 2026
- Ownership
- Direct
* marks a reported price that did not pass the local price check.